Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Jun. 30, 2014 | Jul. 31, 2014 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Jun-14 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Trading Symbol | 'VIVO | ' |
Entity Registrant Name | 'MERIDIAN BIOSCIENCE INC | ' |
Entity Central Index Key | '0000794172 | ' |
Current Fiscal Year End Date | '--09-30 | ' |
Entity Filer Category | 'Large Accelerated Filer | ' |
Entity Common Stock, Shares Outstanding | ' | 41,567,521 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 |
Income Statement [Abstract] | ' | ' | ' | ' |
NET REVENUES | $47,212 | $47,108 | $142,140 | $139,724 |
COST OF SALES | 17,970 | 16,477 | 53,298 | 49,554 |
GROSS PROFIT | 29,242 | 30,631 | 88,842 | 90,170 |
OPERATING EXPENSES | ' | ' | ' | ' |
Research and development | 3,146 | 2,711 | 9,185 | 8,039 |
Selling and marketing | 6,249 | 5,440 | 18,787 | 16,604 |
General and administrative | 6,715 | 6,781 | 20,446 | 21,484 |
Total operating expenses | 16,110 | 14,932 | 48,418 | 46,127 |
OPERATING INCOME | 13,132 | 15,699 | 40,424 | 44,043 |
OTHER INCOME (EXPENSE) | ' | ' | ' | ' |
Interest income | 5 | 12 | 15 | 38 |
Other, net | -257 | -160 | -505 | 225 |
Total other income (expense) | -252 | -148 | -490 | 263 |
EARNINGS BEFORE INCOME TAXES | 12,880 | 15,551 | 39,934 | 44,306 |
INCOME TAX PROVISION | 4,045 | 5,392 | 13,373 | 15,424 |
NET EARNINGS | $8,835 | $10,159 | $26,561 | $28,882 |
BASIC EARNINGS PER COMMON SHARE | $0.21 | $0.25 | $0.64 | $0.70 |
DILUTED EARNINGS PER COMMON SHARE | $0.21 | $0.24 | $0.63 | $0.69 |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC | 41,478 | 41,304 | 41,445 | 41,209 |
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS | 618 | 679 | 669 | 654 |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED | 42,096 | 41,983 | 42,114 | 41,863 |
ANTI-DILUTIVE SECURITIES: | ' | ' | ' | ' |
Common share options and restricted shares and units | 337 | 256 | 161 | 295 |
DIVIDENDS DECLARED PER COMMON SHARE | $0.20 | $0.19 | $0.59 | $0.57 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Comprehensive Income (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 |
Statement Of Income And Comprehensive Income [Abstract] | ' | ' | ' | ' |
Net earnings | $8,835 | $10,159 | $26,561 | $28,882 |
Foreign currency translation adjustment | 361 | 154 | 1,421 | -817 |
COMPREHENSIVE INCOME | $9,196 | $10,313 | $27,982 | $28,065 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Jun. 30, 2014 | Jun. 30, 2013 |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings | $26,561 | $28,882 |
Non-cash items included in net earnings: | ' | ' |
Depreciation of property, plant and equipment | 2,634 | 2,522 |
Amortization of intangible assets | 1,549 | 1,715 |
Amortization of deferred illumigene instrument costs | 1,281 | 1,131 |
Stock-based compensation | 2,662 | 1,984 |
Deferred income taxes | -438 | -1,356 |
Loss on disposition and write-down of fixed assets and other assets | 22 | 30 |
Change in current assets | -6,804 | -3,125 |
Change in current liabilities | -4,055 | 951 |
Other, net | 199 | -220 |
Net cash provided by operating activities | 23,611 | 32,514 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Purchases of property, plant and equipment | -3,968 | -2,193 |
Purchases of intangible assets | -1,687 | -20 |
Net cash used for investing activities | -5,655 | -2,213 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Dividends paid | -24,464 | -23,500 |
Proceeds and tax benefits from exercises of stock options | 629 | 2,094 |
Net cash used for financing activities | -23,835 | -21,406 |
Effect of Exchange Rate Changes on Cash and Equivalents | 882 | -125 |
Net (Decrease) Increase in Cash and Equivalents | -4,997 | 8,770 |
Cash and Equivalents at Beginning of Period | 44,282 | 31,593 |
Cash and Equivalents at End of Period | $39,285 | $40,363 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Jun. 30, 2014 | Sep. 30, 2013 |
In Thousands, unless otherwise specified | ||
CURRENT ASSETS | ' | ' |
Cash and equivalents | $39,285 | $44,282 |
Accounts receivable, less allowances of $214 and $233 | 25,806 | 26,183 |
Inventories | 37,605 | 34,835 |
Prepaid expenses and other current assets | 6,423 | 4,643 |
Deferred income taxes | 4,331 | 4,145 |
Total current assets | 113,450 | 114,088 |
PROPERTY, PLANT AND EQUIPMENT, at Cost | ' | ' |
Land | 1,184 | 1,183 |
Buildings and improvements | 26,930 | 26,848 |
Machinery, equipment and furniture | 39,225 | 38,502 |
Construction in progress | 2,982 | 554 |
Subtotal | 70,321 | 67,087 |
Less: accumulated depreciation and amortization | 43,014 | 40,996 |
Net property, plant and equipment | 27,307 | 26,091 |
OTHER ASSETS | ' | ' |
Goodwill | 23,826 | 23,115 |
Other intangible assets, net | 8,472 | 8,057 |
Restricted cash | 1,000 | 1,000 |
Deferred illumigene instrument costs, net | 2,982 | 3,270 |
Deferred income taxes | 1,380 | 823 |
Other assets | 346 | 304 |
Total other assets | 38,006 | 36,569 |
TOTAL ASSETS | 178,763 | 176,748 |
CURRENT LIABILITIES | ' | ' |
Accounts payable | 6,416 | 5,592 |
Accrued employee compensation costs | 3,914 | 9,670 |
Other accrued expenses | 5,738 | 5,462 |
Income taxes payable | 875 | 979 |
Total current liabilities | 16,943 | 21,703 |
COMMITMENTS AND CONTINGENCIES | ' | ' |
SHAREHOLDERS' EQUITY | ' | ' |
Preferred stock, no par value, 1,000,000 shares authorized, none issued | ' | ' |
Common shares, no par value, 71,000,000 shares authorized, 41,564,271 and 41,517,839 shares issued, respectively | ' | ' |
Additional paid-in capital | 110,669 | 107,412 |
Retained earnings | 48,985 | 46,888 |
Accumulated other comprehensive income | 2,166 | 745 |
Total shareholders' equity | 161,820 | 155,045 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $178,763 | $176,748 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parenthetical) (USD $) | Jun. 30, 2014 | Sep. 30, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
Statement Of Financial Position [Abstract] | ' | ' |
Allowances for accounts receivable | $214 | $233 |
Preferred stock, par value | ' | ' |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value | ' | ' |
Common stock, shares authorized | 71,000,000 | 71,000,000 |
Common stock, shares issued | 41,564,271 | 41,517,839 |
Condensed_Consolidated_Stateme3
Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) (USD $) | Total | Common Shares Issued [Member] | Additional Paid-In Capital [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income [Member] |
In Thousands, except Share data | USD ($) | USD ($) | USD ($) | USD ($) | |
Beginning balance at Sep. 30, 2013 | $155,045 | ' | $107,412 | $46,888 | $745 |
Beginning balance, Shares at Sep. 30, 2013 | 41,517,839 | 41,517,839 | ' | ' | ' |
Cash dividends paid | -24,464 | ' | ' | -24,464 | ' |
Exercise of stock options | 595 | ' | 595 | ' | ' |
Exercise of stock options, Shares | ' | 44,000 | ' | ' | ' |
Conversion of restricted stock units | ' | 3,000 | ' | ' | ' |
Cancellation of restricted shares | ' | -1,000 | ' | ' | ' |
Stock compensation expense | 2,662 | ' | 2,662 | ' | ' |
Net earnings | 26,561 | ' | ' | 26,561 | ' |
Foreign currency translation adjustment | 1,421 | ' | ' | ' | 1,421 |
Ending balance at Jun. 30, 2014 | $161,820 | ' | $110,669 | $48,985 | $2,166 |
Ending balance, Shares at Jun. 30, 2014 | 41,564,271 | 41,564,271 | ' | ' | ' |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended | |
Jun. 30, 2014 | ||
Accounting Policies [Abstract] | ' | |
Basis of Presentation | ' | |
1 | Basis of Presentation | |
The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of June 30, 2014, the results of its operations for the three and nine month periods ended June 30, 2014 and 2013, and its cash flows for the nine month periods ended June 30, 2014 and 2013. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2013 Annual Report on Form 10-K. Financial information as of September 30, 2013 has been derived from the Company’s audited consolidated financial statements. | ||
The results of operations for interim periods are not necessarily indicative of the results to be expected for the year. |
Significant_Accounting_Policie
Significant Accounting Policies | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Significant Accounting Policies | ' | ||||||||||||||||
2 | Significant Accounting Policies | ||||||||||||||||
(a) | Revenue Recognition and Accounts Receivable – | ||||||||||||||||
Revenue is generally recognized from sales when product is shipped and title has passed to the customer. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of certain of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were $4,074 at June 30, 2014 and $3,866 at September 30, 2013, and have been netted against accounts receivable. | |||||||||||||||||
Revenue for our Diagnostics segment includes revenue for our illumigene® molecular test system. This system includes an instrument, instrument accessories and test kits. In markets where the test system is sold via multiple deliverable arrangements (i.e., the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories are deferred upon placement at a customer and amortized on a straight-line basis into cost of sales over the expected utilization period, generally three years. | |||||||||||||||||
We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period, in order to accommodate customer set-up and installation. There is de minimis consideration received from the customer at the time of instrument placement. We have determined that the instrument and instrument accessories are not a separate unit of accounting because such equipment can only be used to process and read the results from our illumigene diagnostic tests (i.e., our instrument and test kits function together to deliver a diagnostic test result), and therefore the instrument and instrument accessories do not have standalone value to the customer. Consequently, there is no revenue allocated to the placement of the instrument and instrument accessories. Test kits are delivered to the customer over the utilization period of the instrument, which we estimate has a useful life of three years. Our average customer contract period, including estimated renewals, is at least equal to the estimated three-year utilization period. Revenue for the sale of test kits is recognized upon shipment and transfer of title to the customers. | |||||||||||||||||
In markets where the test system is not sold via multiple deliverable arrangements (i.e., countries other than the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, our illumigene molecular test system is sold to independent distributors who inventory the instruments, instrument accessories and test kits for resale to end-users. | |||||||||||||||||
Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. | |||||||||||||||||
Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Depending on the nature of the arrangement, revenue is recognized as services are performed and billed, upon completion and acceptance by the customer, or upon delivery of product and acceptance by the customer. | |||||||||||||||||
Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. | |||||||||||||||||
(b) | Comprehensive Income (Loss) – | ||||||||||||||||
As reflected in the accompanying Condensed Consolidated Statements of Comprehensive Income, our comprehensive income or loss is comprised of net earnings and foreign currency translation. | |||||||||||||||||
Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in non-functional currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations. | |||||||||||||||||
(c) | Income Taxes – | ||||||||||||||||
The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates. | |||||||||||||||||
We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations. | |||||||||||||||||
In September 2013, the Internal Revenue Service issued Treasury Decision 9636, which enacted final tax regulations regarding the capitalization and expensing of amounts paid to acquire, produce, or improve tangible property. The regulations also include guidance regarding the retirement of depreciable property. The regulations are required to be effective in taxable years beginning on or after January 1, 2014, although taxpayers may choose to apply them in taxable years beginning on or after January 1, 2012. Our adoption of these regulations on October 1, 2014 is not expected to have a significant impact on the Company’s consolidated results of operations, cash flows or financial position. | |||||||||||||||||
(d) | Stock-based Compensation – | ||||||||||||||||
We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service periods. | |||||||||||||||||
(e) | Cash and Cash Equivalents – | ||||||||||||||||
Cash and cash equivalents include the following components: | |||||||||||||||||
June 30, 2014 | September 30, 2013 | ||||||||||||||||
Cash and | Other | Cash and | Other | ||||||||||||||
Equivalents | Equivalents | ||||||||||||||||
Overnight repurchase agreements | $ | 24,074 | $ | — | $ | 32,103 | $ | — | |||||||||
Cash on hand - | |||||||||||||||||
Restricted | — | 1,000 | — | 1,000 | |||||||||||||
Unrestricted | 15,211 | — | 12,179 | — | |||||||||||||
Total | $ | 39,285 | $ | 1,000 | $ | 44,282 | $ | 1,000 | |||||||||
(f) | Recent Accounting Pronouncements – | ||||||||||||||||
In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes and replaces nearly all currently-existing U.S. GAAP revenue recognition guidance including related disclosure requirements. This guidance will be effective for the Company beginning October 1, 2017. The Company has not yet assessed the impact that adoption of this guidance will have on its financial statements. | |||||||||||||||||
(g) | Reclassifications – | ||||||||||||||||
Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity. |
Inventories
Inventories | 9 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories | ' | ||||||||
3 | Inventories | ||||||||
Inventories are comprised of the following: | |||||||||
June 30, | September 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 5,960 | $ | 7,170 | |||||
Work-in-process | 10,457 | 8,585 | |||||||
Finished goods - illumigene instruments | 1,993 | 1,980 | |||||||
Finished goods - kits and reagents | 19,195 | 17,100 | |||||||
Total | $ | 37,605 | $ | 34,835 | |||||
Reportable_Segment_and_Major_C
Reportable Segment and Major Customers Information | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||
Reportable Segment and Major Customers Information | ' | ||||||||||||||||
4 | Reportable Segment and Major Customers Information | ||||||||||||||||
Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. | |||||||||||||||||
In the fourth quarter of fiscal 2013, we aggregated our Diagnostics operating segments into a single reportable segment, thereby resulting in our reportable segments being Diagnostics and Life Science. The prior period information reflected herein has been conformed to the current period presentation. | |||||||||||||||||
The Diagnostics segment is headquartered in Cincinnati, Ohio, which also serves as the base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including a sales and business development location in Singapore. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. | |||||||||||||||||
Amounts due from two Diagnostics distributor customers accounted for 15% and 17% of consolidated accounts receivable at June 30, 2014 and September 30, 2013, respectively. Revenue from these two distributor customers accounted for 36% and 40% of the Diagnostics segment third-party revenue during the three months ended June 30, 2014 and 2013, respectively, and 36% and 43% during the nine months ended June 30, 2014 and 2013, respectively. In addition, approximately $3,400 and $3,500 of our accounts receivable at June 30, 2014 and September 30, 2013, respectively, is due from Italian hospital customers whose funding ultimately comes from the Italian government, representing 13% of consolidated accounts receivable in each of the respective periods. | |||||||||||||||||
Within our Life Science segment, two diagnostic manufacturing customers accounted for 15% and 18% of the segment’s third-party revenue during the three months ended June 30, 2014 and 2013, respectively, and 16% and 18% during the nine months ended June 30, 2014 and 2013, respectively. | |||||||||||||||||
Segment information for the interim periods is as follows: | |||||||||||||||||
Diagnostics | Life | Eliminations(1) | Total | ||||||||||||||
Science | |||||||||||||||||
Three Months Ended June 30, 2014 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 35,168 | $ | 12,044 | $ | — | $ | 47,212 | |||||||||
Inter-segment | 99 | 374 | (473 | ) | — | ||||||||||||
Operating income | 10,526 | 2,676 | (70 | ) | 13,132 | ||||||||||||
Goodwill (June 30, 2014) | 1,250 | 22,576 | — | 23,826 | |||||||||||||
Other intangible assets, net (June 30, 2014) | 2,853 | 5,619 | — | 8,472 | |||||||||||||
Total assets (June 30, 2014) | 111,208 | 68,200 | (645 | ) | 178,763 | ||||||||||||
Three Months Ended June 30, 2013 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 35,305 | $ | 11,803 | $ | — | $ | 47,108 | |||||||||
Inter-segment | 185 | 356 | (541 | ) | — | ||||||||||||
Operating income | 12,296 | 3,543 | (140 | ) | 15,699 | ||||||||||||
Goodwill (September 30, 2013) | 1,250 | 21,865 | — | 23,115 | |||||||||||||
Other intangible assets, net (September 30, 2013) | 1,561 | 6,496 | — | 8,057 | |||||||||||||
Total assets (September 30, 2013) | 111,719 | 65,393 | (364 | ) | 176,748 | ||||||||||||
Nine Months Ended June 30, 2014 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 107,066 | $ | 35,074 | $ | — | $ | 142,140 | |||||||||
Inter-segment | 362 | 858 | (1,220 | ) | — | ||||||||||||
Operating income | 32,211 | 8,243 | (30 | ) | 40,424 | ||||||||||||
Nine Months Ended June 30, 2013 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 107,377 | $ | 32,347 | $ | — | $ | 139,724 | |||||||||
Inter-segment | 388 | 864 | (1,252 | ) | — | ||||||||||||
Operating income | 36,130 | 8,223 | (310 | ) | 44,043 | ||||||||||||
-1 | Eliminations consist of inter-segment transactions. | ||||||||||||||||
Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation. |
Intangible_Assets
Intangible Assets | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||||||||||||||
Intangible Assets | ' | ||||||||||||||||
5 | Intangible Assets | ||||||||||||||||
A summary of our acquired intangible assets subject to amortization, as of June 30, 2014 and September 30, 2013 is as follows: | |||||||||||||||||
June 30, 2014 | September 30, 2013 | ||||||||||||||||
Gross | Accumulated | Gross | Accumulated | ||||||||||||||
Carrying | Amortization | Carrying | Amortization | ||||||||||||||
Value | Value | ||||||||||||||||
Manufacturing technologies, core products and cell lines | $ | 11,762 | $ | 10,512 | $ | 11,676 | $ | 10,097 | |||||||||
Trademarks, licenses and patents | 6,543 | 2,663 | 4,748 | 2,130 | |||||||||||||
Customer lists and supply agreements | 12,584 | 9,242 | 12,353 | 8,493 | |||||||||||||
$ | 30,889 | $ | 22,417 | $ | 28,777 | $ | 20,720 | ||||||||||
During the first quarter of fiscal 2014, we acquired the remaining licensing rights related to patents that are part of our illumigene molecular technology for $1,638. These rights are being amortized over a weighted average period of approximately 8.5 years. | |||||||||||||||||
The actual aggregate amortization expense for these intangible assets was $507 and $550 for the three months ended June 30, 2014 and 2013, respectively, and $1,549 and $1,715 for the nine months ended June 30, 2014 and 2013, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2019 is as follows: remainder of fiscal 2014 – $482, fiscal 2015 – $1,797, fiscal 2016 – $1,451, fiscal 2017 – $1,177, fiscal 2018 – $1,154 and fiscal 2019 – $1,113. |
Significant_Accounting_Policie1
Significant Accounting Policies (Policies) | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Revenue Recognition and Accounts Receivable | ' | ||||||||||||||||
(a) | Revenue Recognition and Accounts Receivable – | ||||||||||||||||
Revenue is generally recognized from sales when product is shipped and title has passed to the customer. Revenue for the Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of certain of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were $4,074 at June 30, 2014 and $3,866 at September 30, 2013, and have been netted against accounts receivable. | |||||||||||||||||
Revenue for our Diagnostics segment includes revenue for our illumigene® molecular test system. This system includes an instrument, instrument accessories and test kits. In markets where the test system is sold via multiple deliverable arrangements (i.e., the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories are deferred upon placement at a customer and amortized on a straight-line basis into cost of sales over the expected utilization period, generally three years. | |||||||||||||||||
We evaluate whether each deliverable in the arrangement is a separate unit of accounting. The significant deliverables are an instrument, instrument accessories (e.g., printer) and test kits. An instrument and instrument accessories are delivered to the customer prior to the start of the customer utilization period, in order to accommodate customer set-up and installation. There is de minimis consideration received from the customer at the time of instrument placement. We have determined that the instrument and instrument accessories are not a separate unit of accounting because such equipment can only be used to process and read the results from our illumigene diagnostic tests (i.e., our instrument and test kits function together to deliver a diagnostic test result), and therefore the instrument and instrument accessories do not have standalone value to the customer. Consequently, there is no revenue allocated to the placement of the instrument and instrument accessories. Test kits are delivered to the customer over the utilization period of the instrument, which we estimate has a useful life of three years. Our average customer contract period, including estimated renewals, is at least equal to the estimated three-year utilization period. Revenue for the sale of test kits is recognized upon shipment and transfer of title to the customers. | |||||||||||||||||
In markets where the test system is not sold via multiple deliverable arrangements (i.e., countries other than the United States, Australia, Belgium, France, Holland and Italy), the cost of the instrument and instrument accessories is charged to cost of sales at the time of shipment and transfer of title to the customer. Revenue for the sales of instruments and instrument accessories and test kits is recognized upon shipment and transfer of title to the customers. In these markets, our illumigene molecular test system is sold to independent distributors who inventory the instruments, instrument accessories and test kits for resale to end-users. | |||||||||||||||||
Our products are generally not subject to a customer right of return except for product recall events under the rules and regulations of the Food and Drug Administration or equivalent agencies outside the United States. In this circumstance, the costs to replace affected products would be accrued at the time a loss was probable and estimable. | |||||||||||||||||
Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Depending on the nature of the arrangement, revenue is recognized as services are performed and billed, upon completion and acceptance by the customer, or upon delivery of product and acceptance by the customer. | |||||||||||||||||
Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments under local contracts and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on historical write-off experience. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. | |||||||||||||||||
Comprehensive Income (Loss) | ' | ||||||||||||||||
(b) | Comprehensive Income (Loss) – | ||||||||||||||||
As reflected in the accompanying Condensed Consolidated Statements of Comprehensive Income, our comprehensive income or loss is comprised of net earnings and foreign currency translation. | |||||||||||||||||
Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in non-functional currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations. | |||||||||||||||||
Income Taxes | ' | ||||||||||||||||
(c) | Income Taxes – | ||||||||||||||||
The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates. | |||||||||||||||||
We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations. | |||||||||||||||||
In September 2013, the Internal Revenue Service issued Treasury Decision 9636, which enacted final tax regulations regarding the capitalization and expensing of amounts paid to acquire, produce, or improve tangible property. The regulations also include guidance regarding the retirement of depreciable property. The regulations are required to be effective in taxable years beginning on or after January 1, 2014, although taxpayers may choose to apply them in taxable years beginning on or after January 1, 2012. Our adoption of these regulations on October 1, 2014 is not expected to have a significant impact on the Company’s consolidated results of operations, cash flows or financial position. | |||||||||||||||||
Stock-based Compensation | ' | ||||||||||||||||
(d) | Stock-based Compensation – | ||||||||||||||||
We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service periods. | |||||||||||||||||
Cash and Cash Equivalents | ' | ||||||||||||||||
(e) | Cash and Cash Equivalents – | ||||||||||||||||
Cash and cash equivalents include the following components: | |||||||||||||||||
June 30, 2014 | September 30, 2013 | ||||||||||||||||
Cash and | Other | Cash and | Other | ||||||||||||||
Equivalents | Equivalents | ||||||||||||||||
Overnight repurchase agreements | $ | 24,074 | $ | — | $ | 32,103 | $ | — | |||||||||
Cash on hand - | |||||||||||||||||
Restricted | — | 1,000 | — | 1,000 | |||||||||||||
Unrestricted | 15,211 | — | 12,179 | — | |||||||||||||
Total | $ | 39,285 | $ | 1,000 | $ | 44,282 | $ | 1,000 | |||||||||
Recent Accounting Pronouncements | ' | ||||||||||||||||
(f) | Recent Accounting Pronouncements – | ||||||||||||||||
In May 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes and replaces nearly all currently-existing U.S. GAAP revenue recognition guidance including related disclosure requirements. This guidance will be effective for the Company beginning October 1, 2017. The Company has not yet assessed the impact that adoption of this guidance will have on its financial statements. | |||||||||||||||||
Reclassifications | ' | ||||||||||||||||
(g) | Reclassifications – | ||||||||||||||||
Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity. |
Significant_Accounting_Policie2
Significant Accounting Policies (Tables) | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | ' | ||||||||||||||||
Components of Cash and Cash Equivalents | ' | ||||||||||||||||
Cash and cash equivalents include the following components: | |||||||||||||||||
June 30, 2014 | September 30, 2013 | ||||||||||||||||
Cash and | Other | Cash and | Other | ||||||||||||||
Equivalents | Equivalents | ||||||||||||||||
Overnight repurchase agreements | $ | 24,074 | $ | — | $ | 32,103 | $ | — | |||||||||
Cash on hand - | |||||||||||||||||
Restricted | — | 1,000 | — | 1,000 | |||||||||||||
Unrestricted | 15,211 | — | 12,179 | — | |||||||||||||
Total | $ | 39,285 | $ | 1,000 | $ | 44,282 | $ | 1,000 | |||||||||
Inventories_Tables
Inventories (Tables) | 9 Months Ended | ||||||||
Jun. 30, 2014 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Components of Inventories | ' | ||||||||
Inventories are comprised of the following: | |||||||||
June 30, | September 30, | ||||||||
2014 | 2013 | ||||||||
Raw materials | $ | 5,960 | $ | 7,170 | |||||
Work-in-process | 10,457 | 8,585 | |||||||
Finished goods - illumigene instruments | 1,993 | 1,980 | |||||||
Finished goods - kits and reagents | 19,195 | 17,100 | |||||||
Total | $ | 37,605 | $ | 34,835 | |||||
Reportable_Segment_and_Major_C1
Reportable Segment and Major Customers Information (Tables) | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Segment Reporting [Abstract] | ' | ||||||||||||||||
Segment Information | ' | ||||||||||||||||
Segment information for the interim periods is as follows: | |||||||||||||||||
Diagnostics | Life | Eliminations(1) | Total | ||||||||||||||
Science | |||||||||||||||||
Three Months Ended June 30, 2014 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 35,168 | $ | 12,044 | $ | — | $ | 47,212 | |||||||||
Inter-segment | 99 | 374 | (473 | ) | — | ||||||||||||
Operating income | 10,526 | 2,676 | (70 | ) | 13,132 | ||||||||||||
Goodwill (June 30, 2014) | 1,250 | 22,576 | — | 23,826 | |||||||||||||
Other intangible assets, net (June 30, 2014) | 2,853 | 5,619 | — | 8,472 | |||||||||||||
Total assets (June 30, 2014) | 111,208 | 68,200 | (645 | ) | 178,763 | ||||||||||||
Three Months Ended June 30, 2013 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 35,305 | $ | 11,803 | $ | — | $ | 47,108 | |||||||||
Inter-segment | 185 | 356 | (541 | ) | — | ||||||||||||
Operating income | 12,296 | 3,543 | (140 | ) | 15,699 | ||||||||||||
Goodwill (September 30, 2013) | 1,250 | 21,865 | — | 23,115 | |||||||||||||
Other intangible assets, net (September 30, 2013) | 1,561 | 6,496 | — | 8,057 | |||||||||||||
Total assets (September 30, 2013) | 111,719 | 65,393 | (364 | ) | 176,748 | ||||||||||||
Nine Months Ended June 30, 2014 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 107,066 | $ | 35,074 | $ | — | $ | 142,140 | |||||||||
Inter-segment | 362 | 858 | (1,220 | ) | — | ||||||||||||
Operating income | 32,211 | 8,243 | (30 | ) | 40,424 | ||||||||||||
Nine Months Ended June 30, 2013 | |||||||||||||||||
Net revenues - | |||||||||||||||||
Third-party | $ | 107,377 | $ | 32,347 | $ | — | $ | 139,724 | |||||||||
Inter-segment | 388 | 864 | (1,252 | ) | — | ||||||||||||
Operating income | 36,130 | 8,223 | (310 | ) | 44,043 | ||||||||||||
-1 | Eliminations consist of inter-segment transactions. |
Intangible_Assets_Tables
Intangible Assets (Tables) | 9 Months Ended | ||||||||||||||||
Jun. 30, 2014 | |||||||||||||||||
Goodwill And Intangible Assets Disclosure [Abstract] | ' | ||||||||||||||||
Summary of Acquired Intangible Assets Subject to Amortization | ' | ||||||||||||||||
A summary of our acquired intangible assets subject to amortization, as of June 30, 2014 and September 30, 2013 is as follows: | |||||||||||||||||
June 30, 2014 | September 30, 2013 | ||||||||||||||||
Gross | Accumulated | Gross | Accumulated | ||||||||||||||
Carrying | Amortization | Carrying | Amortization | ||||||||||||||
Value | Value | ||||||||||||||||
Manufacturing technologies, core products and cell lines | $ | 11,762 | $ | 10,512 | $ | 11,676 | $ | 10,097 | |||||||||
Trademarks, licenses and patents | 6,543 | 2,663 | 4,748 | 2,130 | |||||||||||||
Customer lists and supply agreements | 12,584 | 9,242 | 12,353 | 8,493 | |||||||||||||
$ | 30,889 | $ | 22,417 | $ | 28,777 | $ | 20,720 | ||||||||||
Significant_Accounting_Policie3
Significant Accounting Policies - Additional Information (Detail) (USD $) | 9 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Jun. 30, 2014 | Sep. 30, 2013 |
Accounting Policies [Abstract] | ' | ' |
Accrued distributor price adjustments | $4,074 | $3,866 |
Expected instrument utilization period | '3 years | ' |
Period of review of accounts individually | '90 days | ' |
Likelihood percentage of tax benefit being recognized upon ultimate settlement | 50.00% | ' |
Tax benefits recognized from uncertain tax positions measurement | 'Greater than 50% likely of being ultimately realized upon settlement | ' |
Significant_Accounting_Policie4
Significant Accounting Policies - Components of Cash and Cash Equivalents (Detail) (USD $) | Jun. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||||
Cash and Cash Equivalents [Line Items] | ' | ' | ' | ' |
Cash on hand - Restricted | $1,000 | $1,000 | ' | ' |
Total | 39,285 | 44,282 | 40,363 | 31,593 |
Cash and Cash Equivalents [Member] | ' | ' | ' | ' |
Cash and Cash Equivalents [Line Items] | ' | ' | ' | ' |
Overnight repurchase agreements | 24,074 | 32,103 | ' | ' |
Cash on hand - Restricted | 0 | 0 | ' | ' |
Cash on hand - Unrestricted | 15,211 | 12,179 | ' | ' |
Total | 39,285 | 44,282 | ' | ' |
Other [Member] | ' | ' | ' | ' |
Cash and Cash Equivalents [Line Items] | ' | ' | ' | ' |
Overnight repurchase agreements | 0 | 0 | ' | ' |
Cash on hand - Restricted | 1,000 | 1,000 | ' | ' |
Cash on hand - Unrestricted | 0 | 0 | ' | ' |
Total | $1,000 | $1,000 | ' | ' |
Inventories_Components_of_Inve
Inventories - Components of Inventories (Detail) (USD $) | Jun. 30, 2014 | Sep. 30, 2013 |
In Thousands, unless otherwise specified | ||
Inventory [Line Items] | ' | ' |
Raw materials | $5,960 | $7,170 |
Work-in-process | 10,457 | 8,585 |
Total | 37,605 | 34,835 |
Illumigene instruments [Member] | ' | ' |
Inventory [Line Items] | ' | ' |
Finished goods | 1,993 | 1,980 |
Kits and reagents [Member] | ' | ' |
Inventory [Line Items] | ' | ' |
Finished goods | $19,195 | $17,100 |
Reportable_Segment_and_Major_C2
Reportable Segment and Major Customers Information - Additional Information (Detail) (USD $) | 9 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||
In Thousands, unless otherwise specified | Jun. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 |
Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Life Science [Member] | Accounts Receivable [Member] | Accounts Receivable [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | Sales Revenue, Net [Member] | |
Customer | ITALY | ITALY | Customer | Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Diagnostics [Member] | Life Science [Member] | Life Science [Member] | Life Science [Member] | Life Science [Member] | ||
Hospital Customers [Member] | Hospital Customers [Member] | ITALY | ITALY | ||||||||||||
Hospital Customers [Member] | Hospital Customers [Member] | ||||||||||||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of customers | 2 | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts due from customers | 15.00% | 17.00% | ' | ' | ' | 13.00% | 13.00% | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of segment's Third Party Sales | ' | ' | ' | ' | ' | ' | ' | 36.00% | 40.00% | 36.00% | 43.00% | 15.00% | 18.00% | 16.00% | 18.00% |
Account receivable | ' | ' | $3,400 | $3,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reportable_Segment_and_Major_C3
Reportable Segment and Major Customers Information - Segment Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Thousands, unless otherwise specified | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Sep. 30, 2013 |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net sales - Third-party | $47,212 | $47,108 | $142,140 | $139,724 | ' |
Net sales - Inter-segment | ' | ' | ' | ' | ' |
Operating income | 13,132 | 15,699 | 40,424 | 44,043 | ' |
Goodwill | 23,826 | ' | 23,826 | ' | 23,115 |
Other intangible assets, net | 8,472 | ' | 8,472 | ' | 8,057 |
Total assets | 178,763 | ' | 178,763 | ' | 176,748 |
Operating Segments [Member] | Diagnostics [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net sales - Third-party | 35,168 | 35,305 | 107,066 | 107,377 | ' |
Net sales - Inter-segment | 99 | 185 | 362 | 388 | ' |
Operating income | 10,526 | 12,296 | 32,211 | 36,130 | ' |
Goodwill | 1,250 | ' | 1,250 | ' | 1,250 |
Other intangible assets, net | 2,853 | ' | 2,853 | ' | 1,561 |
Total assets | 111,208 | ' | 111,208 | ' | 111,719 |
Operating Segments [Member] | Life Science [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net sales - Third-party | 12,044 | 11,803 | 35,074 | 32,347 | ' |
Net sales - Inter-segment | 374 | 356 | 858 | 864 | ' |
Operating income | 2,676 | 3,543 | 8,243 | 8,223 | ' |
Goodwill | 22,576 | ' | 22,576 | ' | 21,865 |
Other intangible assets, net | 5,619 | ' | 5,619 | ' | 6,496 |
Total assets | 68,200 | ' | 68,200 | ' | 65,393 |
Eliminations [Member] | ' | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Net sales - Third-party | ' | ' | ' | ' | ' |
Net sales - Inter-segment | -473 | -541 | -1,220 | -1,252 | ' |
Operating income | -70 | -140 | -30 | -310 | ' |
Goodwill | ' | ' | ' | ' | ' |
Other intangible assets, net | ' | ' | ' | ' | ' |
Total assets | ($645) | ' | ($645) | ' | ($364) |
Intangible_Assets_Summary_of_A
Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) (USD $) | Jun. 30, 2014 | Sep. 30, 2013 |
In Thousands, unless otherwise specified | ||
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Value | $30,889 | $28,777 |
Accumulated Amortization | 22,417 | 20,720 |
Manufacturing technologies, core products and cell lines [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Value | 11,762 | 11,676 |
Accumulated Amortization | 10,512 | 10,097 |
Trademarks, licenses and patents [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Value | 6,543 | 4,748 |
Accumulated Amortization | 2,663 | 2,130 |
Customer lists and supply agreements [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Gross Carrying Value | 12,584 | 12,353 |
Accumulated Amortization | $9,242 | $8,493 |
Intangible_Assets_Additional_I
Intangible Assets - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 |
Amortization Of Intangible Assets [Line Items] | ' | ' | ' | ' |
Amortization of intangible assets | $507 | $550 | $1,549 | $1,715 |
Estimated amortization expense for intangible assets remainder of fiscal year 2014 | 482 | ' | 482 | ' |
2015 | 1,797 | ' | 1,797 | ' |
2016 | 1,451 | ' | 1,451 | ' |
2017 | 1,177 | ' | 1,177 | ' |
2018 | 1,154 | ' | 1,154 | ' |
2019 | 1,113 | ' | 1,113 | ' |
Illumigene Molecular Technology [Member] | ' | ' | ' | ' |
Amortization Of Intangible Assets [Line Items] | ' | ' | ' | ' |
Licensing rights acquired | $1,638 | ' | $1,638 | ' |
Licensing Agreements [Member] | Illumigene Molecular Technology [Member] | ' | ' | ' | ' |
Amortization Of Intangible Assets [Line Items] | ' | ' | ' | ' |
Weighted average amortization period | ' | ' | '8 years 6 months | ' |